External‐beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society

Kiess, Ana P.; Agrawal, Nishant; Brierley, James D.; Duvvuri, Umamaheswar; Ferris, Robert L.; Genden, Eric; Wong, Richard J.; Tuttle, R. Michael; Lee, Nancy Y.; Randolph, Gregory W.

doi:10.1002/hed.24357

Cited by 84 publications

(62 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Schwartz et al [23] described their prescription of the following doses: the operative bed is treated to adjuvant doses of 57–60 Gy, microscopic positive surgical margins can be boosted to doses of 63 Gy, and gross disease is treated to doses of 66–70 Gy. Similar radiation dose recommendations were recently published by the American Head and Neck Society [1]. Additional investigation is necessary to define the optimal curative dose prescriptions for PTC [23].…”

Section: Discussionmentioning

confidence: 83%

The role of adjuvant external beam radiation therapy for papillary thyroid carcinoma invading the trachea

et al. 2017

View full text Add to dashboard Cite

PurposeTo evaluate the effect of adjuvant external beam radiation therapy (EBRT) on local failure-free survival rate (LFFS) for papillary thyroid cancer (PTC) invading the trachea.Materials and MethodsFifty-six patients with locally advanced PTC invading the trachea were treated with surgical resection. After surgery, 21 patients received adjuvant EBRT and radioactive iodine therapy (EBRT group) and 35 patients were treated with radioactive iodine therapy (control group).ResultsThe age range was 26–87 years (median, 56 years). The median follow-up period was 43 months (range, 4 to 145 months). EBRT doses ranged from 50.4 to 66 Gy (median, 60 Gy). Esophagus invasion and gross residual disease was more frequent in the EBRT group. In the control group, local recurrence developed in 9 (9/35, 26%) and new distant metastasis in 2 (2/35, 6%) patients, occurring 4 to 68 months (median, 37 months) and 53 to 68 months (median, 60 months) after surgery, respectively. Two patients had simultaneous local recurrence and new distant metastasis. There was one local failure in the EBRT group at 18 months after surgery (1/21, 5%). The 5-year LFFS was 95% in the EBRT group and 63% in the control group (p = 0.103). In the EBRT group, one late grade 2 xerostomia was developed.ConclusionAlthough, EBRT group had a higher incidence of esophagus invasion and gross residual disease, EBRT group showed a better 5-year LFFS. Adjuvant EBRT may have contributed to the better LFFS in these patients.

show abstract

Section: Discussionmentioning

confidence: 83%

The role of adjuvant external beam radiation therapy for papillary thyroid carcinoma invading the trachea

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, it is unclear whether this is an endorsement of EBRT use in this setting. A recent statement by the AHNS recommends EBRT for patients with gross residual or unresectable locoregional disease, except in patients younger than 45 years old with limited radioiodine‐avid gross disease . The statement recommends against routine use of EBRT after complete resection of gross disease.…”

Section: Discussionmentioning

confidence: 99%

“…The most recent American Thyroid Association (ATA) guidelines recommend against routine use of EBRT after initial complete surgical removal of tumor due to lack of supporting evidence in the literature . Similarly, a recent statement by the American Head and Neck Society (AHNS) recommends against routine use of EBRT after complete resection of gross disease …”

Section: Introductionmentioning

confidence: 99%

Adjuvant external beam radiotherapy for locally invasive papillary thyroid cancer

Megwalu

Orloff

2019

Head & Neck

View full text Add to dashboard Cite

Background The goal of this study was to assess the impact of adjuvant external beam radiotherapy (EBRT) on survival in patients with locally invasive papillary thyroid carcinoma. Methods Propensity score analysis was performed on 870 patients with surgically resected T4 papillary thyroid carcinoma, identified in the Surveillance, Epidemiology, and End Results Database between 1988 and 2013. Results EBRT was associated with worse overall survival (OS) (HR 1.60, 95% CI 1.18‐2.16) and disease‐specific survival (DSS) (HR 1.58, 1.09‐2.30). Subset analysis of patients with major extrathyroidal invasion showed that EBRT was associated with worse OS (HR 1.53, 95% CI 1.04‐2.25), but not with DSS (HR 1.57, 95% CI 0.99‐2.50). Conclusion Adjuvant EBRT, in the initial management of locally invasive papillary thyroid cancer, was not associated with a survival benefit. Future studies are needed to determine which subset of patients may benefit from adjuvant EBRT.

show abstract

“…Partial thickness resections of the esophageal wall, tracheal windowing with reconstruction, and partial laryngectomy are potentially valuable techniques permitting tumor resection without the morbidity of more extensive procedures or concerns surrounding microscopic residual tumor . Adjuvant external‐beam radiotherapy may be used in this setting …”

Section: Recommendation #3mentioning

confidence: 99%

Comprehensive management of recurrent thyroid cancer: An American Head and Neck Society consensus statement

et al. 2016

View full text Add to dashboard Cite

This American Head and Neck Society (AHNS) consensus statement focuses on the detection and management of recurrent thyroid cancer. This document describes the radiologic approach to defining structural recurrent disease and the operative and nonoperative rationale in addressing identified structural disease to create equipoise in the personalized treatment strategy for the patient. The recommendations of this AHNS multidisciplinary consensus panel of the American Head and Neck Society are intended to help guide all multidisciplinary clinicians who diagnose or manage adult patients with thyroid cancer. The consensus panel is comprised of members of the American Head and Neck Society and its Endocrine Surgical Committee, and there is representation from medical endocrinology and both national and international surgical representation drawn from general/endocrine surgery and otolaryngology/head and neck surgery. Authors provided expertise for their respective sections, and consensus recommendations were made regarding the evaluation and treatment of recurrent thyroid cancer. Evidence‐based literature support is drawn from thyroid cancer studies, recurrent thyroid cancer studies, and American Thyroid Association (ATA) guidelines. The manuscript was then distributed to members of the American Head and Neck Society Endocrine Committee and governing counsel for further feedback. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1862–1869, 2016

show abstract

External‐beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society

Cited by 84 publications

References 60 publications

The role of adjuvant external beam radiation therapy for papillary thyroid carcinoma invading the trachea

The role of adjuvant external beam radiation therapy for papillary thyroid carcinoma invading the trachea

Adjuvant external beam radiotherapy for locally invasive papillary thyroid cancer

Comprehensive management of recurrent thyroid cancer: An American Head and Neck Society consensus statement

Contact Info

Product

Resources

About